Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma.

DeTemple VK, Kaatz M, Stockfleth E, Scheel C, Angela Y, Gutzmer R, Leiter U, Meier F, Schadendorf D, Livingstone E, Gebhardt C, von Wasielewski I, Weichenthal M, Mohr P, Hassel J, Pföhler C, Simon JC, Jochims F, Terheyden P, Ulrich J, Haferkamp S, Drexler K, Schilling B, Glutsch V, Heinzerling L, Berking C, Ugurel S, Tomsitz D

Open source

DOI: 10.1016/j.ejca.2025.115590
Published: 2025 Jul 25
Container: European journal of cancer (Oxford, England : 1990)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2025.115590,
  title = {Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma.},
  author = {DeTemple VK and Kaatz M and Stockfleth E and Scheel C and Angela Y and Gutzmer R and Leiter U and Meier F and Schadendorf D and Livingstone E and Gebhardt C and von Wasielewski I and Weichenthal M and Mohr P and Hassel J and Pföhler C and Simon JC and Jochims F and Terheyden P and Ulrich J and Haferkamp S and Drexler K and Schilling B and Glutsch V and Heinzerling L and Berking C and Ugurel S and Tomsitz D},
  year = {2025},
  journal = {European journal of cancer (Oxford, England : 1990)},
  doi = {10.1016/j.ejca.2025.115590},
  url = {https://doi.org/10.1016/j.ejca.2025.115590}
}

RIS

TY  - JOUR
TI  - Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma.
AU  - DeTemple VK
AU  - Kaatz M
AU  - Stockfleth E
AU  - Scheel C
AU  - Angela Y
AU  - Gutzmer R
AU  - Leiter U
AU  - Meier F
AU  - Schadendorf D
AU  - Livingstone E
AU  - Gebhardt C
AU  - von Wasielewski I
AU  - Weichenthal M
AU  - Mohr P
AU  - Hassel J
AU  - Pföhler C
AU  - Simon JC
AU  - Jochims F
AU  - Terheyden P
AU  - Ulrich J
AU  - Haferkamp S
AU  - Drexler K
AU  - Schilling B
AU  - Glutsch V
AU  - Heinzerling L
AU  - Berking C
AU  - Ugurel S
AU  - Tomsitz D
PY  - 2025
JO  - European journal of cancer (Oxford, England : 1990)
DO  - 10.1016/j.ejca.2025.115590
UR  - https://doi.org/10.1016/j.ejca.2025.115590
ER  -

APA

VK, D., M, K., E, S., C, S., Y, A., R, G., U, L., F, M., D, S., E, L., C, G., I, V. W., M, W., P, M., J, H., C, P., JC, S., F, J., P, T., J, U., S, H., K, D., B, S., V, G., L, H., C, B., S, U., & D, T. (2025). Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma.. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2025.115590

Source records

pubmed · retrieved 2026-09-26T18:47:50.946Z